Open an account

CervoMed

CRVO · NASDAQ

$2.29−$0.02 (−0.87%)TodayMarket closed ·
Prev close $2.31

About CRVO

CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Employees
15
Headquarters
Boston, Massachusetts
Listed
Nov 9, 2016
Sector
Health Care
Industry
Biotechnology
Website
cervomed.com

CRVO key statistics

Market cap
34.62M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
317.00K
Volume
136.35K
Open price
$2.28
High today
$2.41
Low today
$2.28
52 Week high
$10.00
52 Week low
$2.13

CervoMed (CRVO) at a glance

As of Oct 20, 2026, CervoMed (CRVO) shares are priced at $2.29, giving the company a market cap of 34.62M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.28 and $2.41. The current price is 0.4% above the day's low and 4.8% below its high.

Volume so far is 136.35K shares, below the average of 317.00K shares a day.

Over the past year CervoMed has ranged from $2.13 to $10.00, and now sits 2% of the way up that range.

CervoMed met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.64 per share against an estimate of -$0.8857.

The average analyst price target is $15.71, 585.9% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $15.71
Low
$7.07
Now
$2.29
High
$26.25

CRVO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 22.2% on average.

  1. Q3 FY24: reported -$0.55 per share against an estimate of -$0.4208
  2. Q4 FY24: reported -$0.80 per share against an estimate of -$0.6426
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$0.6724
  4. Q2 FY25: reported -$0.70 per share against an estimate of -$0.6426
  5. Q3 FY25: reported -$0.84 per share against an estimate of -$0.7874
  6. Q4 FY25: reported -$0.88 per share against an estimate of -$0.7315
  7. Q1 FY26: reported -$0.86 per share against an estimate of -$0.7956
  8. Q2 FY26: reported -$0.64 per share against an estimate of -$0.8857

CRVO news

  • Vandana Singh

    CervoMed Shows Progress in Treating Rare Aphasia Condition

  • Press releaseGlobe Newswire

    Wall Street Chases the Next Big Breakout

  • Press releaseGlobe Newswire

    Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    CervoMed to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

  • Vandana Singh

    CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

  • Press releaseGlobe Newswire

    CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Similar companies

Companies in the same industry as CervoMed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.